Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504023 · ClinicalTrials.gov registry record · NA
Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva
A NA study of Vulvar Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT00504023: Completed NA study of Vulvar Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00504023 is a NA study of Vulvar Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants, below the 453-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00504023, a NA study of Vulvar Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.
Primary Outcome
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Conditions Studied
Interventions
- PROCEDURE biopsy
- PROCEDURE therapeutic conventional surgery
- DRUG imiquimod
Study Locations (2)
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-04 |
| Est. Completion | 2018-01 |
| Phase | NA |
What the finished NCT00504023 record still lists
NCT00504023 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 453-participant average among 17 other Vulvar Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Vulvar Cancer appearing as the primary indexed condition, and to 3 interventions - of which biopsy is the first listed.
NCT00504023 reports a single indexed study location in New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT00504023 about?
NCT00504023 is a clinical study titled "Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva". RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imi...
What is the current status of trial NCT00504023?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2007-04. Estimated completion is 2018-01.
What conditions does trial NCT00504023 study?
This clinical trial studies the following conditions: Vulvar Cancer.
What interventions are being tested in trial NCT00504023?
The interventions under investigation include: biopsy (PROCEDURE), therapeutic conventional surgery (PROCEDURE), imiquimod (DRUG).
Who is sponsoring clinical trial NCT00504023?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00504023 being conducted?
This trial has 2 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00504023's enrollment target sits among peer trials
8 18th of 17 the lowest of 17 other Vulvar Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vulvar Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
-
Image-Guided Gynecologic Brachytherapy
RECRUITING · NA
-
Serial MRI Scans During Radiation Therapy
RECRUITING · NA
-
Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer
ACTIVE NOT RECRUITING · NA
-
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia